CNS Pharmaceuticals, Inc. reported earnings results for the first quarter ended March 31, 2022. For the first quarter, the company reported net loss was USD 2.78 million compared to USD 3.61 million a year ago. Basic loss per share from continuing operations was USD 2.1 compared to USD 4.5 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.2155 USD | -1.14% | +0.70% | -83.03% |
04-30 | Transcript : CNS Pharmaceuticals, Inc. - Shareholder/Analyst Call | |
04-23 | Transcript : CNS Pharmaceuticals, Inc. - Special Call |
1st Jan change | Capi. | |
---|---|---|
-83.03% | 2.32M | |
+26.28% | 42.68B | |
-3.99% | 42.4B | |
+45.32% | 40.04B | |
-6.20% | 28.31B | |
+6.36% | 24.94B | |
-21.47% | 18.96B | |
+27.58% | 12.3B | |
-2.75% | 11.95B | |
-2.02% | 11.55B |
- Stock Market
- Equities
- CNSP Stock
- News CNS Pharmaceuticals, Inc.
- CNS Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022